1. Home
  2. Press release
Apr 05, 2019 10:45 JST

Source: Eisai

Eisai to Launch "Travelmin Support" as Series' First Quasi-Drug
Motion Sickness Solution Now Available in Convenience Stores

TOKYO, Apr 05, 2019 - (JCN Newswire) - Eisai Co., Ltd. will launch the mouth freshener Travelmin Support as the first quasi-drug of the Travelmin series which can be purchased even at convenience stores and others in Japan on Monday, April 8.

Travelmin Support is a quasi-drug that contains plant derived daylily extract as its main ingredient to help with motion sickness and discomfort. As a drop-type product, it is easy for children to take, and it has a refreshing cider flavor. Each drop is individually wrapped for convenience, is easy to carry around, and can be taken by both adults and children five of age and older.

After hearing the voices of many consumers who had difficulties because they forgot to purchase motion sickness medicine and were unable to obtain any during their travels, Eisai decided to launch Travelmin Support as a quasi-drug that can be purchased even at convenience stores and others.

The Travelmin series is widely familiar in Japan as a national brand of motion sickness medicines. In addition to Travelmin, which was introduced in 1952, Eisai has launched the drop-type product Travelmin Churop (class 2 pharmaceutical product) which can be taken even after becoming sick, Travelmin R (class 2 pharmaceutical product) which contains ingredients that comparatively cause less sleepiness, and others. With the introduction of Travelmin Support to the Travelmin lineup, Eisai will continue to contribute to people concerned about motion sickness and discomfort when traveling, as well as help consumers enjoy their travels.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: Healthcare & Pharm

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
June 02 2025 16:46 JST
 
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
May 28 2025 16:45 JST
 
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
May 21 2025 14:00 JST
 
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro
May 16 2025 16:21 JST
 
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
April 30 2025 13:17 JST
 
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
April 18 2025 15:52 JST
 
Eisai to Divest Rights for Pariet in China to Peak Pharma
April 01 2025 12:15 JST
 
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
March 25 2025 16:28 JST
 
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
March 25 2025 11:21 JST
 
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
March 10 2025 19:24 JST
 
More Press release >>

Latest Press Release


Fujitsu to develop ETF trading platform based on TSE's CONNEQTOR and provide it to Australian Securities Exchange
Jul 03, 2025 11:14 JST

Mitsubishi Motors Launches the All-New Grandis for the European Market
Jul 02, 2025 12:10 JST

Valuufy partners with Mainichi Future Creation Lab, Supporting New Approaches to Business Sustainability
Jul 02, 2025 12:00 JST

Fujitsu launches solution to enhance customers' global supply chain resilience
Jul 02, 2025 11:32 JST

MHI Receives Order to Supply Four Circulating Water Pumps for Units 5 and 6 of Sanmen Nuclear Power Plant in China Under Collaboration with Dongfang Electric Machinery
Jul 02, 2025 11:30 JST

Multi-purpose Arena in Odaiba Aomi Area TOYOTA ARENA TOKYO Construction Completed
Jul 01, 2025 22:56 JST

1Finity, a Fujitsu company, commences operations and reveals brand identity
Jul 01, 2025 22:53 JST

MHI Thermal Systems Begins Field Test of Jointly Developed "Surplus Renewable Energy Absorption and Release System"
Jul 01, 2025 22:40 JST

Japan's Telecommunications Carriers Strengthen Disaster Response Through Collaborative Information Sharing
Jul 01, 2025 22:30 JST

JCB and Mandai Wildlife Group Deepen Partnership with exclusive discounts for JCB cardmembers
Jul 01, 2025 16:00 JST

Fujitsu provides Japan's first AI-powered cloud-based library search service
Jul 01, 2025 11:30 JST

JCB Brings Apple Pay to Cardmembers in Vietnam
Jul 01, 2025 11:15 JST

First Shipment of LNG from the LNG Canada Project
Jul 01, 2025 11:00 JST

Approval in Principle (AiP) for World's First LCO2 / Methanol Carrier
Jun 30, 2025 20:30 JST

Acropolis Rally Greece: Day 4 Sunday success and second overall for TOYOTA GAZOO Racing's Ogier
Jun 30, 2025 20:15 JST

Mitsubishi Fuso-Hino Merger: 4 Firms Collaborate for the Future of Commercial Vehicles
Jun 30, 2025 20:10 JST

Six Companies Establish BlueRebirth Council to Expand Use of Recycled Materials in New Vehicles
Jun 30, 2025 19:25 JST

Honda Changes Plan to Build New Production Plant for Next-generation Fuel Cell Module in Japan
Jun 30, 2025 19:20 JST

MHI-AC&R Receives Recommendation Award of JARAC's 42nd Excellent Energy Saving Equipment Awards
Jun 30, 2025 19:00 JST

The University of Osaka and Fujitsu Japan launch joint research on AI-powered education support for culturally and linguistically diverse children in Japan
Jun 30, 2025 12:00 JST
 More Latest Release >>